Who are DiaMedica Therapeutics's investors?

DiaMedica Therapeutics's investors include CentreStone Ventures, Shepherd Ventures.

How much funding has DiaMedica Therapeutics raised?

DiaMedica Therapeutics has disclosed $110.4M raised across 6 rounds.

Where is DiaMedica Therapeutics headquartered?

DiaMedica Therapeutics is headquartered in Minneapolis, US.

DiaMedica Therapeutics

NASDAQ: DMAC

Minneapolis, US · Canada (Federal Level) corporation · 2 known investors

Find your way into DiaMedica Therapeutics

247 people in our graph share verified history with the DiaMedica Therapeutics team — schools, employers, funds. One of them is your warm intro.

Nicole Vitullounlockedknows Lorianne Masuoka · together at Marinus Pharma (overlapped)

×5knows the team · via Yale School of Medicine

knows the team · via University of South Dakota

knows the team · via Vanderbilt University Medical Center

knows the team · via Five Prime Therapeutics, Inc.

×2knows the team · via University of North Dakota

DiaMedica Therapeutics develops therapies aimed at reducing ischemia in patients with serious vascular diseases, with an initial focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. It is a clinical-stage biopharmaceutical company working on treatments for ischemic disorders.

Biotech Digital Health

Founders & leadership

David J. Wambeke inChief Business Officer2023–2025David J. Wambeke is an Executive Officer at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic disorders. He is a former healthcare investment banker and U.S. Army combat veteran.

Lorianne Masuoka inChief Medical Officer2024–2025Lorianne Masuoka is an executive officer at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies to reduce ischemia in patients with serious vascular diseases, including preeclampsia, fetal growth restriction, and acute ischemic stroke. She has expertise in neurology and related therapeutic areas.

Rick Pauls inPresident & CEORick Pauls is an Executive Officer and Director at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic diseases including acute ischemic stroke and preeclampsia.

Scott Kellen inChief Financial OfficerScott Kellen is an executive officer at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic disorders including preeclampsia and acute ischemic stroke. He brings financial and operational management experience, with expertise in capital formation, SEC compliance, financial planning, and corporate governance.

Todd Verdoorn inChief Scientific Officer2016–2019Todd Verdoorn is an executive officer at DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic disorders. He has led drug and device development programs from preclinical through clinical stages across multiple companies and disease areas, with experience in manufacturing, toxicology, biomarkers, and translational medicine.

Julie Krop inChief Medical OfficerJulie Krop is Chief Medical Officer of DiaMedica Therapeutics, a clinical-stage biopharmaceutical company developing therapies for ischemic vascular disorders. She has held senior clinical development and regulatory affairs roles at large pharmaceutical and biotech companies, with experience spanning early-stage through post-approval drug development and FDA interactions.

Paul PapiNamed on SEC filing

Zhenyu (Jerry) XiaoNamed on SEC filing

David GurveyNamed on SEC filing

Board

Charles P. SembaBoard director

Richard KuntzBoard directorManaging Director at Shepherd Ventures

R. Michael GiuffreBoard director

Investors · 2

CentreStone Venturesreported · 2 sourcesWinnipeg · $182.5K – $1.8M

Shepherd VenturesreportedSan Diego · $750K – $3Mvia Richard P. Kuntz · board

Reported raises · per SEC filings

Form D private placements

$110.4M disclosed across 6 rounds · 2018–2025

▶$30.1MraisedJul 2025 · 14 investors · Biotechnology

Rule 506(b)